Amgen Inc. $AMGN Stock Holdings Trimmed by First Dallas Securities Inc.

First Dallas Securities Inc. lessened its position in shares of Amgen Inc. (NASDAQ:AMGN) by 18.9% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,115 shares of the medical research company’s stock after selling 1,193 shares during the period. First Dallas Securities Inc.’s holdings in Amgen were worth $1,428,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Wealth Preservation Advisors LLC acquired a new position in Amgen in the first quarter worth $25,000. CBIZ Investment Advisory Services LLC lifted its position in shares of Amgen by 1,214.3% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company’s stock worth $29,000 after buying an additional 85 shares during the last quarter. Legacy Investment Solutions LLC bought a new position in shares of Amgen in the 2nd quarter worth about $27,000. Activest Wealth Management boosted its holdings in shares of Amgen by 3,433.3% in the 1st quarter. Activest Wealth Management now owns 106 shares of the medical research company’s stock valued at $33,000 after buying an additional 103 shares during the period. Finally, Quaker Wealth Management LLC grew its position in shares of Amgen by 200.0% during the 2nd quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock valued at $34,000 after buying an additional 240 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the sale, the senior vice president directly owned 7,209 shares in the company, valued at $2,141,000.91. This represents a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.76% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Bank of America raised their target price on shares of Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a report on Friday, September 26th. Wall Street Zen raised Amgen from a “hold” rating to a “buy” rating in a report on Saturday. Citigroup boosted their price objective on Amgen from $310.00 to $315.00 and gave the company a “neutral” rating in a research report on Wednesday, September 24th. Cantor Fitzgerald upped their price objective on Amgen from $305.00 to $315.00 and gave the stock a “neutral” rating in a research note on Thursday. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of Amgen in a research report on Wednesday. Eight analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $308.83.

Amgen Price Performance

Shares of AMGN opened at $320.20 on Monday. Amgen Inc. has a one year low of $253.30 and a one year high of $335.88. The stock’s fifty day moving average is $289.94 and its 200-day moving average is $288.65. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The firm has a market capitalization of $172.42 billion, a price-to-earnings ratio of 26.18, a price-to-earnings-growth ratio of 2.61 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. The firm had revenue of $9.56 billion during the quarter, compared to analyst estimates of $8.98 billion. Amgen had a net margin of 18.96% and a return on equity of 174.71%. Amgen’s revenue was up 12.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 12th. Investors of record on Friday, November 21st will be paid a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Friday, November 21st. Amgen’s dividend payout ratio (DPR) is currently 73.57%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.